Your browser doesn't support javascript.
loading
A subunit vaccine against pneumonia: targeting Streptococcus pneumoniae and Klebsiella pneumoniae.
Rafi, Md Oliullah; Al-Khafaji, Khattab; Mandal, Santi M; Meghla, Nigar Sultana; Biswas, Polash Kumar; Rahman, Md Shahedur.
Afiliação
  • Rafi MO; Bioinformatics and Microbial Biotechnology Laboratory, Department of Genetic Engineering and Biotechnology, Jashore University of Science and Technology, Jashore, 7408 Bangladesh.
  • Al-Khafaji K; Department of Genetic Engineering and Biotechnology, Jashore University of Science and Technology, Jashore, 7408 Bangladesh.
  • Mandal SM; College of Dentistry, The University of Mashreq, Baghdad, Iraq.
  • Meghla NS; Central Research Facility, Indian Institute of Technology Kharagpur, Kharagpur, 721302 India.
  • Biswas PK; Department of Microbiology, Jashore University of Science and Technology, Jashore, 7408 Bangladesh.
  • Rahman MS; Department of Stem Cell and Regenerative Biotechnology, Incurable Disease Animal Model & Stem Cell Institute (IDASI), Konkuk University, 120 Neungdong-ro, Gwangjin-gu, Seoul, 05029 South Korea.
Article em En | MEDLINE | ID: mdl-37096010
ABSTRACT
Community-acquired pneumonia is primarily caused by Streptococcus pneumoniae and Klebsiella pneumoniae, two pathogens that have high morbidity and mortality rates. This is largely due to bacterial resistance development against current antibiotics and the lack of effective vaccines. The objective of this work was to develop an immunogenic multi-epitope subunit vaccine capable of eliciting a robust immune response against S. pneumoniae and K. pneumoniae. The targeted proteins were the pneumococcal surface proteins (PspA and PspC) and choline-binding protein (CbpA) of S. pneumoniae and the outer membrane proteins (OmpA and OmpW) of K. pneumoniae. Different computational approaches and various immune filters were employed for designing a vaccine. The immunogenicity and safety of the vaccine were evaluated by utilizing many physicochemical and antigenic profiles. To improve structural stability, disulfide engineering was applied to a portion of the vaccine structure with high mobility. Molecular docking was performed to examine the binding affinities and biological interactions at the atomic level between the vaccine and Toll-like receptors (TLR2 and 4). Further, the dynamic stabilities of the vaccine and TLRs complexes were investigated by molecular dynamics simulations. While the immune response induction capability of the vaccine was assessed by the immune simulation study. Vaccine translation and expression efficiency was determined through an in silico cloning experiment utilizing the pET28a(+) plasmid vector. The obtained results revealed that the designed vaccine is structurally stable and able to generate an effective immune response to combat pneumococcal infection. Supplementary Information The online version contains supplementary material available at 10.1007/s13721-023-00416-3.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 4_TD Base de dados: MEDLINE Idioma: En Revista: Netw Model Anal Health Inform Bioinform Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 4_TD Base de dados: MEDLINE Idioma: En Revista: Netw Model Anal Health Inform Bioinform Ano de publicação: 2023 Tipo de documento: Article